701 - 483 - 3599
Menu
X
  • Home
  • About Us
    • Capabilities
    • Why Orphanos?
    • Meet Our Team
  • Services
    • Biostatistics and Programming
    • Clinical Management
    • Data Management
    • Medical Affairs
    • Patient Recruitment
    • Safety and Pharmacovigilance
  • Rare Disease Focus
  • Global Reach
  • Careers
  • Request RFP
  • Resources
    • Blog
    • Free White Paper
    • Clinical Trial Management System
    • Enroll In Study
  • Contact Us

Home • Blog • News

NORD Issues Statement as House Committees Review the American Health Care Act

Washington, D.C., March 8, 2017—The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, issued the following statement in advance… Read more

Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for the Treatment of Myasthenia Gravis

CORAL GABLES, Fla., Sept. 02, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today… Read more

Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A

–  Actimab-A has received Orphan Drug Designation in the U.S. –  Orphan Designation in the EU can result in regulatory assistance, reduced fees and 10 years of market exclusivity NEW… Read more

  • About Us
  • Capabilities
  • Why Orphanos?
  • Meet Our Team
  • Careers
Free White Paper. PDF Download Free White Paper: 2016 Overview of Novel Orphan Drugs

Latest Blogs

Latest News

NORD Issues Statement as House Committees Review the American Health Care Act

20th March 2017 | Orphanos

Washington, D.C., March 8, 2017—The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, issued the following statement in advance... Read more

Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for the Treatment of Myasthenia Gravis

21st February 2017 | Orphanos

CORAL GABLES, Fla., Sept. 02, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today... Read more

Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A

16th February 2017 | Orphanos

–  Actimab-A has received Orphan Drug Designation in the U.S. –  Orphan Designation in the EU can result in regulatory assistance, reduced fees and 10 years of market exclusivity NEW... Read more

Request for Proposal

  • Should be Empty:

Contact Us

Location

116 Villard St. W,
Dickinson, ND 58601

Telephone: 701 - 483 - 3599

/

Fax: 701 - 483 - 1556

© Copyright Orphanos 2022 | Privacy Policy | Terms of Use

Mankato Web Design